Climb Bio (CLYM) EBITDA (2020 - 2026)

Climb Bio has reported EBITDA for 7 years, with the latest figure at -$14.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 31.77% year-over-year to -$14.0 million; the trailing twelve-month figure through Mar 2026 stood at -$52.9 million (up 42.91% YoY), and the FY2025 full-year result was -$59.4 million, up 19.54% from the prior year.
• EBITDA for Q1 2026 stood at -$14.0 million, up from -$17.6 million in the prior quarter.
• The five-year high for EBITDA was -$1.7 million in Q1 2024, with the low at -$54.9 million in Q2 2024.
• Historically, EBITDA has averaged -$13.4 million across 5 years, with a median of -$9.7 million in 2022.
• Annual changes were most pronounced in 2024 — EBITDA soared 92.3% — and 2025, when it plunged 1110.5%.
• Climb Bio's EBITDA stood at -$7.5 million in 2022, then jumped by 51.82% to -$3.6 million in 2023, then slumped by 136.62% to -$8.6 million in 2024, then tumbled by 104.21% to -$17.6 million in 2025, then climbed by 20.23% to -$14.0 million in 2026.
• The last three EBITDA figures came in at -$14.0 million (Q1 2026), -$17.6 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.